Priti Kambli1, Kanchan Ajbani1, Meeta Sadani1, Chaitali Nikam1, Anjali Shetty1, Zarir Udwadia2, Timothy C Rodwell3, Antonino Catanzaro3, Camilla Rodrigues4. 1. Section Microbiology, Department of Laboratory Medicine, P.D. Hinduja National Hospital and Medical Research Center, Mumbai, India. 2. Section Pulmonology, Department of Medicine, P.D. Hinduja National Hospital and Medical Research Center, Mumbai, India. 3. University of California, San Diego, Department of Medicine, San Diego, CA, USA. 4. Section Microbiology, Department of Laboratory Medicine, P.D. Hinduja National Hospital and Medical Research Center, Mumbai, India. Electronic address: dr_crodrigues@hindujahospital.com.
Abstract
OBJECTIVE: To correlate gyrA mutations found on the Genotype MTBDRsl assay in Mycobacterium tuberculosis (MTB) isolates with Minimum Inhibitory Concentrations (MICs) to the fluoroquinolones compounds ofloxacin (OFX) and moxifloxacin (MXF). METHODS: MICs for OFX and MXF were ascertained for 93 archived clinical MTB isolates that showed gyrA mutations at Ala90Val, Ser91Pro, Asp94Ala, Asn/Tyr, Gly and His. Thirty fluoroquinolones susceptible isolates as determined by presence of all wild-type gyrA bands on the Genotype MTBDRsl assay were also included. RESULTS: gyrA mutations at Ala90Val (n = 25), Ser91Pro (n = 6), Asp94Ala (n = 4), Asp94Asn/Tyr (n = 13), Asp94Gly (n = 42) and Asp94His (n = 3) were observed. Isolates with mutations at Ala90Val or Ser91Pro had MIC90 of 4.0 μg/ml and 1.0 μg/ml for OFX and MXF, respectively, and isolates with mutations at Asp 94Ala, Asn/Tyr, Gly and His had MIC90 of 8.0 μg/ml, and 2.5 μg/ml for OFX and MXF, respectively. CONCLUSIONS: MTB MICs were found to be consistently lower for MXF than for OFX among isolates with the same gyrA mutation (e.g. Ala90Val). The majority of MTB isolates containing mutations at Asp94Ala, Asn/Tyr, Gly and His in gyrA were associated with a moderate level of resistance to MXF (MIC = 2.5 μg/ml), although 3 isolates with the mutations Asp94Asn/Tyr/Gly were associated with a high level of resistance to both fluoroquinolones (MXF MICs = 5.0-8.0 μg/ml, OFX MICs = ≥10.0 μg/ml).
OBJECTIVE: To correlate gyrA mutations found on the Genotype MTBDRsl assay in Mycobacterium tuberculosis (MTB) isolates with Minimum Inhibitory Concentrations (MICs) to the fluoroquinolones compounds ofloxacin (OFX) and moxifloxacin (MXF). METHODS: MICs for OFX and MXF were ascertained for 93 archived clinical MTB isolates that showed gyrA mutations at Ala90Val, Ser91Pro, Asp94Ala, Asn/Tyr, Gly and His. Thirty fluoroquinolones susceptible isolates as determined by presence of all wild-type gyrA bands on the Genotype MTBDRsl assay were also included. RESULTS:gyrA mutations at Ala90Val (n = 25), Ser91Pro (n = 6), Asp94Ala (n = 4), Asp94Asn/Tyr (n = 13), Asp94Gly (n = 42) and Asp94His (n = 3) were observed. Isolates with mutations at Ala90Val or Ser91Pro had MIC90 of 4.0 μg/ml and 1.0 μg/ml for OFX and MXF, respectively, and isolates with mutations at Asp 94Ala, Asn/Tyr, Gly and His had MIC90 of 8.0 μg/ml, and 2.5 μg/ml for OFX and MXF, respectively. CONCLUSIONS:MTB MICs were found to be consistently lower for MXF than for OFX among isolates with the same gyrA mutation (e.g. Ala90Val). The majority of MTB isolates containing mutations at Asp94Ala, Asn/Tyr, Gly and His in gyrA were associated with a moderate level of resistance to MXF (MIC = 2.5 μg/ml), although 3 isolates with the mutations Asp94Asn/Tyr/Gly were associated with a high level of resistance to both fluoroquinolones (MXF MICs = 5.0-8.0 μg/ml, OFX MICs = ≥10.0 μg/ml).
Authors: Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry Journal: J Antimicrob Chemother Date: 2012-01-25 Impact factor: 5.790
Authors: Elena Yu Nosova; Anastasia A Bukatina; Yulia D Isaeva; Marina V Makarova; Ksenia Yu Galkina; Arkadyi M Moroz Journal: J Med Microbiol Date: 2012-09-27 Impact factor: 2.472
Authors: Frederick A Sirgel; Robin M Warren; Elizabeth M Streicher; Thomas C Victor; Paul D van Helden; Erik C Böttger Journal: J Antimicrob Chemother Date: 2012-02-22 Impact factor: 5.790
Authors: Sophia B Georghiou; Marva Seifert; Donald G Catanzaro; Richard S Garfein; Timothy C Rodwell Journal: J Clin Microbiol Date: 2017-04-12 Impact factor: 5.948
Authors: S Foongladda; S Banu; S Pholwat; J Gratz; S O-Thong; N Nakkerd; R Chinli; S S Ferdous; S M M Rahman; A Rahman; S Ahmed; S Heysell; M Sariko; G Kibiki; E Houpt Journal: Int J Tuberc Lung Dis Date: 2016-08 Impact factor: 2.373
Authors: Marva Seifert; Edmund Capparelli; Donald G Catanzaro; Timothy C Rodwell Journal: Antimicrob Agents Chemother Date: 2019-06-24 Impact factor: 5.191
Authors: Yingda L Xie; Soumitesh Chakravorty; Derek T Armstrong; Sandra L Hall; Laura E Via; Taeksun Song; Xing Yuan; Xiaoying Mo; Hong Zhu; Peng Xu; Qian Gao; Myungsun Lee; Jongseok Lee; Laura E Smith; Ray Y Chen; Joon Sung Joh; YoungSoo Cho; Xin Liu; Xianglin Ruan; Lili Liang; Nila Dharan; Sang-Nae Cho; Clifton E Barry; Jerrold J Ellner; Susan E Dorman; David Alland Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245
Authors: P Kambli; K Ajbani; C Nikam; A Khillari; A Shetty; Z Udwadia; S B Georghiou; T C Rodwell; A Catanzaro; C Rodrigues Journal: Int J Tuberc Lung Dis Date: 2015-10 Impact factor: 2.373